骨髓增殖性腫瘤精選課件

1、骨髓增殖性腫瘤精選課件骨髓增殖性腫瘤精選課件Pathogenesis and management of essential thrombocythemiaPathogenesis and management ofPathogenesisRelationship of ET to PV and PMF The level of JAK2-STAT5 signaling provides a rheostat that determines whether the disease phenotype is predominantly erythroid or megakaryocytic. P

2、athogenesisRelationship of E Several lines of evidence suggest a blurring of the distinction between these disorders. A proporation of patients diagnosed with ET (see Table 1 for criteria) harbor increased levels of bone marrow reticulin in the absence of other features suggesting a diagnosis of PMF

3、 Several lines of evide The variable degree of reticulin accumulation reflects the combined effects of genetic background, disease duration, therapy, clonal burden and the acquisition of additional genetic lesions. The variable degree of Table 1.Suggested diagnostic criteria for essential thrombocyt

4、hemia(ET) Diagnosis requires A1-A3 OR A1+A3-A5A1 Sustained platelet count 450X109/L.A2 Presence of an acquired pathogenetic mutation(eg, in JAK2 or MPL).A3 No other myeloid malignancy, especially polycythemia vera(PV), primary myelofibrosis(PMF), chronic myeloid leukemia(CML) or myelodysplastic synd

5、rome(MDS).A4 No reactive cause for thrombocytosis and normal iron stores.A5 Bone marrow trephine histology showing increased megakaryocytes with prominent large hyperlobated forms; reticulin is generally not increased(2 on a 0-4 scale).Table 1.Suggested diagnostic c Familial Predisposition to ET and

6、 Other Myeloproliferative Neoplasms A relative risk of 7.4 for developing ET in those with an affected first-degree relative. Familial Predisposition to Are Mutations in JAK2 Disease-initiating Events? The acquisition of a JAK2 mutation was preceded by either a deletion of chromosome 20q24 or a muta

7、tion in TET2. Direct evidence now exists demonstrating that JAK2 mutations are not the disease-initiating event in some patients, although the frequency of this scenario remains unclear.Are Mutations in JAK2 Disease- Progression to Acute Myeloid Leukemia Progression to acute myeloid leukemia(AML) oc

8、curs in a small minority of ET patients and involves the accrual of further genetic events. Progression to Acute Myeloid Diagnosis and Management Diagnostic Criteria Mutations in JAK2 exon 12 are not thought to occur in patients with ET. The combination of an isolated thrombocytosis with a pathogene

9、tic mutation, in the absence of iron deficiency or features of PMF, is usually sufficient to make a diagnosis of ET. Diagnosis and Management Therapy Low-dose aspirin Cytoreductive therapy Hydroxyurea Anagrelide JAK2 inhibitors TherapyIdiopathic erythrocytosis : a disappearing entityIdiopathic eryth

10、rocytosis : a Classification of Erythrocytoses An erythrocytosis can be classified depending on the identified cause. The main division is on the basis of primary causes, where an intrinsic defect in the erythroid progenitor cell is associated with an enhanced response to cytokines; or secondary, wh

11、ere the increased red cell production is driven by factors external to the erythroid compartment, such as increased erythropoietin(EPO) production for any reason. Primary and secondary causes can be classified further as either congenital or acquired(Table2). Classification of ErythrocTable 2.Causes

12、 of an erythrocytosisPrimary ErythrocytosisSecondary erythrocytosisIdiopathic erythrocytosisTable 2.Causes of an erythrocyTable 2.Causes of an erythrocytosisPrimary Erythrocytosis Congenital Erythropoietin(EPO) receptor mutations Acquired Polycythemia vera (including JAK2 exon 12 mutations) Table 2.

13、Causes of an erythrocySecondary erythrocytosis Congenital Defects of the oxygen sensing pathway VHL gene mutation (Chuvash erythrocytosis) PHD2 mutations HIF-2a mutations Other congenital defects High oxygen-affinity hemoglobin Bisphosphoglycerate mutase deficiency Secondary erythrocytosis Acquired

14、EPO-mediated Central hypoxia Chronic lung disease Right-to-left cardiopulmonary vascular shunts Carbon monoxide poisoning Smokers erythrocytosis Hypoventilation syndromes including obstru- ctive sleep apnea High-altitude Acquired Local hypoxia Renal artery stenosis End-stage renal disease Hydronephr

15、osis Renal cysts (polycystic kidney disease) Post-renal transplant erythrocytosis Pathologic EPO production Tumors Cerebellar hemangioblastoma Meningioma Parathyriod carcinoma/adenomas Hepatocellular carcinoma Renal cell cancer Pheochromocytoma Uterine leiomyomas Drug associated Erythropoietin admin

16、istration Androgen administration Pathologic EPO production Investigation of an Erythrocytosis Once an erythrocytosis has been established identification of the cause is the next focus. Clinical Consequences A raised red cell count will increase the viscosity and thus may have clinical consequences.

17、 Management of an Erythrocytosis Reducing the Hct by phlebotomy/venesection reduces the blood viscosity and maybe of benefit. Cytoreductive Low-dose aspirin Investigation of an ErythroTherapeutic potential of JAK2 inhibitorsTherapeutic potential of JAK2 The V617F mutation is localized in a region ou

18、tside the adenosine triphosphate(ATP)-binding pocket of JAK2 enzyme, ATP-competitive inhibitors of JAK2 kinase are not likely to discriminate between wild-type and mutant JAK2 enzymes. Therefore, JAK2 inhibitors, by virtue of their near equipotent activity against wild-type JAK2 that is important fo

19、r normal hematopoiesis, may have adverse myelosuppression as an expected side effect, if administered at doses that aim to completely inhibit the mutant JAK2 enzyme. The V617F mutation is l While they may prove to be effective in controlling hyperproliferation of hematopoietic cells in PV and ET, th

20、ey may not be able to eliminate mutant clones. Most importantly, patients with and without the JAK2 V617F mutation appear to benefit to the same extent. While they may prove toPreliminary clinical observations in selected JAK2 inhibitor trials.AgentCompanyTarget(s)JAK IC50(nM)Current phasePreliminary clinical obserbations in myelofibrosis studiesINCB018424 IncyteJAK1,JAK2JAK1=2.7*JAK2=4.5*JAK3=322*IIIDec